Table A27:

Risk Difference in Response for Pharmacogenomic-Guided Medication Selection Compared With Treatment as Usual Based on HAM-D17

Author, Year	Follow-Up (wk)	(N PGx/TAU)	% Response		Risk Difference (95% CI)	P Valueb
			PGx	TAU
GeneSight
Greden et al, 201957	8	Alla: 621/678 PPa: 560/607	26.1 26	19.8 19.9	0.06 (0.02, 0.11)b 0.06 (0.01, 0.11)b	.007b .01b
Winner et al, 201365	10	25/24	36	20.8	0.15 (−;0.10, 0.40)b	.23b
Hall-Flavin et al, 201355	8	72/93	43.1	26.9	0.16 (0.02, 0.31)b	.03b
Neuropharmagen
Han et al, 201860 Perez et al, 201762	8 12	NR 141/139	64.7 45.4	39.6 40.3	NR 0.05 (−;0.06, 0.17)b	.014c .39b
Genecept
Perlis et al, 202061	8	146/150	39.7	48	–0.08 (−;0.20, 0.03)b	.17
NeuroIDgenetix
Bradley et al, 201858	12 8	140/121d 140/121d	64 49	46 41	0.17 (0.05, 0.29)b,d 0.08 (−;0.4, 0.20)b,d	.0045b .20b
Unspecified Test
Shan et al, 201963	8	ITT: 31/40 PP: 21/27	74.2 90.5	57.5 70.4	0.17 (−;0.05, 0.38)b 0.20 (−;0.01, 0.41)b	.144 .152

Abbreviations: CI, confidence interval; HAM-D17, 17-item Hamilton Depression Rating Scale; ITT, intent to treat; NR, not reported; PGx, pharmacogenomic-guided treatment; PP, per protocol; RR, relative risk, TAU, treatment as usual.

^aFull cohort included all patients who met eligibility criteria. Per-protocol cohort excluded patients with score of < 14 on HAM-D17 at baseline and patients with protocol violations or whose clinicians did not view pharmacogenomic report before baseline. Only patients who completed 8-week follow-up were included in both analyses.

^bCalculated from data provided in study. Estimates might vary from publication owing to variation in statistical analyses used or rounding differences.

^cP value is provided for difference in proportions and might not reflect risk difference.

^dOnly patients with moderate and severe depression were included in analysis (excluded mild depression).